CPRX

Catalyst Pharmaceuticals is a textbook high-quality small-cap specialty pharma: FY2025 revenue grew 19.8% to $589M while net income jumped 30.8% to $214M, driving a 43.8% operating margin, 36.4% net margin, and 22.5% ROE. The five-year trajectory (revenue $141M→$589M, net income $39.5M→$214M from FY2021→FY2025) shows operating leverage from a three-drug portfolio — FIRDAPSE (LEMS), AGAMREE (DMD), and FYCOMPA — and management's R&D spend remains tiny ($12.7M) because the development heavy lift is behind it. The balance sheet is fortress-grade: $709M cash, $954M equity against only $150M liabilities (0.16x), and retained earnings up 66% to $474M. At $31.42 the stock trades at just 18.7x earnings and 6.5x sales — a reasonable multiple for a company compounding earnings at ~30%.

The MD&A confirms management is treating the cash as a strategic asset rather than letting it idle: the Board authorized a fresh $200M buyback (Oct 2025–Dec 2026), of which $39.9M has already been deployed at $22.91 average — well below today's $31.42, meaning shareholders have already booked accretion on those repurchases. FY2025 cash buybacks of $25.3M are modest against $209M operating cash flow, leaving ample room to keep pursuing the BD/acquisition strategy management telegraphs.